Altasciences

Microsampling is a technique involving smaller samples and bigger possibilities:  • Better access to vulnerable patients • New sampling opportunities for clinical trials • Improved shipping logistics • An improved experience for trial participants Hear more from Scientific Director Jeff Plomley, alongside an esteemed panel of guests and host Lisa Sanford, on Episode 3 of 𝘖𝘧𝘧-𝘓𝘢𝘣𝘦𝘭 𝘞𝘪𝘵𝘩 𝘈𝘭𝘵𝘢𝘴𝘤𝘪𝘦𝘯𝘤𝘦𝘴, “The Future of Sampling Is Here—Almost,” available on your preferred podcast platform: 𝗬𝗼𝘂𝗧𝘂𝗯𝗲: https://lnkd.in/esbRJUJr 𝗦𝗽𝗼𝘁𝗶𝗳𝘆: https://lnkd.in/ejWTpB9A 𝗔𝗽𝗽𝗹𝗲 𝗣𝗼𝗱𝗰𝗮𝘀𝘁𝘀: https://lnkd.in/eG4KqvuN #OffLabelWithAltasciences #Microsampling #PatientCentricSampling

Big things are just around the corner! We’re excited to share that the laboratory at our Harleysville, PA, manufacturing facility is expanding. As more sponsors seek integrated support spanning nonclinical through late-phase clinical development, we continue to invest in the infrastructure, expertise, and capabilities needed to grow alongside them. This expansion reflects our commitment to delivering seamless, end-to-end solutions while enhancing the quality and efficiency our partners rely on. #CDMO #Manufacturing #DrugDevelopment #LaboratorySciences

Proud moment for the Altasciences team! We are thrilled to share that Dr. David Nguyen, MD, MBA from our Los Angeles clinic is a published author in the Journal of Clinical Pharmacology! Dr. Dave served as the Principal Investigator on a pivotal clinical trial targeting gliomas, the most common malignant brain tumor in patients under 50. This important research was part of a Japanese ethnobridging study, an area in which our L.A. clinic is highly regarded for its expertise and leadership. Sponsored by Agios Pharmaceuticals (now Servier), this project highlights the immense power of global collaboration in advancing innovative therapies. We are incredibly proud of Dr. Dave and our L.A. team for their dedication to clinical excellence and for helping to accelerate international drug development. Read more about the study and the work behind it here: https://lnkd.in/gsc9ESFF #ClinicalResearch #Oncology #GliomaResearch #DrugDevelopment

Ever wonder what happens inside our 4,000-square-foot bioanalytical lab in Seattle? This is where complex therapeutic programs come to life. From ligand binding assays and flow cytometry to PCR and mass spectrometry, our scientists work across integrated platforms designed to accelerate informed decisions from discovery through clinical development. What we do best: - End-to-end bioanalytical support under GLP/GCLP workflows - qPCR and ddPCR solutions for cell and gene therapy studies - Flow cytometry for immune profiling and biomarker analysis - LC-MS/MS and mass spectrometry for precise quantitative bioanalysis Take the virtual tour and watch as we unveil the invisible: https://lnkd.in/dpqPv64X #Bioanalysis #DrugDevelopment #CRO

Today, we celebrate Clinical Trials Day. A moment to recognize the science, dedication, and human stories behind every breakthrough. Clinical research is where possibility becomes progress. From first-in-human studies to real-world outcomes, each trial represents a step toward safer treatments, better therapies, and ultimately, longer and healthier lives. At Altasciences, we support the full journey of early-phase drug development, intentionally connecting discovery and nonclinical research to clinical proof of concept, to move programs forward faster. But progress isn’t driven by process alone. It’s powered by the patients, volunteers, and research teams who make each study possible. Every protocol executed, every data point generated, and every participant enrolled advances more than a program; it moves critical decisions forward with greater clarity and confidence. Behind every study is a clear objective: helping our partners bring meaningful therapies to patients faster and without compromise. #ClinicalTrialsDay #ClinicalResearch #Innovation #WeAreAltasciences

In honor of Clinical Trials Day, Marketing team member Naif Bartlett is stepping out from behind the camera to give you an insider’s view of a day in the life of a clinical trial participant at our Los Angeles clinic. Happy Clinical Trials Day to the Altascientists at our three clinics in Kansas, Los Angeles, and Montréal, and a special thank you to all participants and clients for their essential role in advancing drug development and helping bring new therapies to patients across the world. Take it away, Naif! #WeAreAltasciences #ClinicalResearch #DrugDevelopment

Our team is on-site at the NorCal SOT Spring Symposium discussing nonclinical strategies that help move new modalities from concept to clinic with confidence. Let’s connect!

Moving from discovery to clinic? The biggest hurdle isn’t just innovation; it’s getting toxicology right. In this issue of 𝘛𝘩𝘦 𝘈𝘭𝘵𝘢𝘴𝘤𝘪𝘦𝘯𝘵𝘪𝘴𝘵, we break down: • How to leverage non-GLP vs. GLP studies to de-risk your program  • The strategic role of study types across modalities • A practical IND/CTA readiness checklist • A case study introducing a novel approach to optimize an IND-enabling study Read the issue and strengthen your path to clinical trials: https://lnkd.in/gFSmuzKt #DrugDevelopment #Toxicology #IND #CRO

Power ups? We don’t need them. With decades of experience from across all areas of early-phase drug development, speed is designed into our approach from the outset, applying the knowledge we’ve accumulated to design optimized, dependable, and forward-thinking programs that accelerate your path to critical milestones. #DrugDevelopmentReimagined #LifeScience

𝗡𝗲𝘄 𝗺𝗼𝗱𝗮𝗹𝗶𝘁𝗶𝗲𝘀 𝗱𝗼𝗻’𝘁 𝗳𝗼𝗹𝗹𝗼𝘄 𝗼𝗹𝗱 𝗽𝗹𝗮𝘆𝗯𝗼𝗼𝗸𝘀. Next week, the Altasciences team is headed to South San Francisco for the NorCal SOT Spring Symposium! Don't miss a featured session by Dr. Norbert Makori, VP of Toxicology, as he outlines nonclinical strategies designed to eliminate bottlenecks and safely accelerate your first-in-human entry. 🗓️ 𝗔𝘁𝘁𝗲𝗻𝗱𝗶𝗻𝗴? Skip the lines and lock in dedicated time to discuss your compound. 👉 Secure your one-on-one meeting here: https://lnkd.in/gYKfkJNw #Toxicology #DrugDevelopment #BioTech Michael Zamora Mark P.